







Non-invasive blood brain barrier mapping in tumor patients by time-encoded arterial spin labelling

<u>Gabriel Hoffmann^{1,2,*}</u>, Christine Preibisch^{1,2}, Matthias Günther³⁻⁵, Amnah Mahroo³, Matthias JP van Osch^{6,7}, Lena Václavů⁶, Lena Schmitzer¹, Claus Zimmer^{1,2}, Benedikt Wiestler¹ and Stephan Kaczmarz^{1,2,8}

Session: Brain Tumors: Acquisition Abstract Nr.: 0141 Time: 13:45 Room: 713A/B



*gabriel.hoffmann@tum.de

¹ Technical University of Munich, School of Medicine, Department of Diagnostic and Interventional Neuroradiology, Munich, Germany ² Technical University of Munich, TUM-Neuroimaging Center, Munich, Germany

³ MR Physics, Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany

⁵ mediri GmbH, Heidelberg, Germany

⁷ Leiden Institute of Brain and Cognition, Leiden University, Leiden, The Netherlands

⁴ MR-Imaging and Spectroscopy, University of Bremen, Bremen, Germany ⁶ C. J. Corter MPI Conter, Department of Badialogy, Leiden, University Medical Conter, Leiden, T.

⁶ C.J. Gorter MRI Center, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands

⁸ Philips GmbH Market DACH, Hamburg, Germany

ISMRM & ISMRT ANNUAL MEETING & EXHIBITION

TORONTO 03-08 JUNE 2023

Declaration of Financial Interests or Relationships

Speaker Name: Gabriel Hoffmann

I have no financial interests or relationships to disclose with regard to the subject matter of this presentation.

How can blood brain barrier (BBB) intergrity be mapped?

Background

- BBB disruptions in high-grade Tumors¹⁻³
- Current methods limited

Purpose Non-invasive, highly sensitive BBB-mapping in clinical scantimes



How can blood brain barrier (BBB) integrity be mapped?

 Hadamard-encoded¹ Arterial Spin Labelling (ASL) with multi-TE readout

• Two-compartment model → Texch^{2,3}

Hypothesis

Method

- Texch is proxy measure for BBB
- Reduced Texch in Tumors



Imaging protocol includes conventional MRI and ASL-BBB mapping



Study population contains patients and age matched HCs



- 14 patients (59.9±15.1y)
- 4 female / 9 male
- High-grade (WHO 3&4) Glioma & Metastasis



- 12 HC (55.5±16.5y)
- 7 female / 5 male

Exemplary data of glioma and metastasis patients



 \rightarrow Visible concordance of T1w & FLAIR data with Texch maps

Exemplary data of glioma and metastasis patients



 \rightarrow Visible concordance of T1w & FLAIR data with Texch maps

How does Texch vary in tumor patients?



Does Texch differ in patients compared to HCs?



ightarrow Patients' Texch reduced even in normal appearing tissue

Is the Texch a reliable proxy for BBB impairments?

Discussion

Decreased Texch in tumor agrees well with literature¹⁻³

Texch values in agreement with previous studies^{2,4}

Reduced Texch in NA-Tissue \rightarrow subtle impairments?

ASL-based Texch mapping sensitive

Texch proxy for BBB integrity

Promising for detecting more subtle impairments (e.g., Alzheimer, small vessel disease)^{5,6}

Summary





Thank you for your attention!

We want to highly appreciate the support by:

German Research Foundation (DFG) Ev. Studienwerk Villigst

